Selected data models

You must log in to select data models for download or further analysis.

24 Search results.
Relevance Rating New first Old first

Intravenous Topotecan and Gemcitabine as Second-line Treatment in Patients With Ovarian Cancer NCT00061308 - Screening - Prior Ovarian Cancer Treatment; Laboratory Tests; Lesion Assessment Record

- 23.08.19 - 1 form, 13 itemgroups, 48 items, 1 language
Itemgroups: Administrative, Prior Ovarian Cancer Treatment - Chemotherapy, Has the patient received radiotherapy?, Prior Ovarian Cancer Treatment - Radiotherapy , Has the patient received prior cancer-related surgery?, Prior Ovarian Cancer Treatment - Surgical Treatment , Has the patient received other cancer-related treatments?, Other Cancer Related Treatments, Laboratory Tests (within 7 days prior to Day 1) - Haematology, Laboratory Tests (within 7 days prior to Day 1) - Haematology , Laboratory Tests (within 7 days prior to Day 1) - Chemistry, Laboratory Tests (within 7 days prior to Day 1) - Chemistry , Lesion Assessment Record
Study ID: 104864/627 Clinical Study ID: 104864/627 Study Title: An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00061308 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Topotecan, Gemcitabine Study Indication: Peritoneal Cancer, Ovarian Cancer, Neoplasms, Ovarian, Fallopian Tube Cancer

Ovarian Cancer NCT00993655 Treatment - NCIC OV 21 Treatment Report Form - 2874225v1.0 - NCIC OV 21 Treatment Report Form

- 20.09.21 - 1 form, 30 itemgroups, 129 items, 1 language
Itemgroups: Patient Information, TIMING OF REPORT, PHYSICAL EXAM, SYSTEMIC THERAPY REPORT, STUDY DRUG ADMINISTRATION - PACLITAXEL, DOSE MODIFICATION TABLE - PACLITAXEL, GFR for Carboplatin dose calculation, STUDY DRUG ADMINISTRATION - CARBOPLATIN, DOSE MODIFICATION TABLE - CARBOPLATIN, STUDY DRUG ADMINISTRATION - CISPLATIN, DOSE MODIFICATION TABLE - CISPLATIN, HOSPITALIZATION, GROWTH FACTORS, SURGERY, ANTI-CANCER TREATMENT, HEMATOLOGY , BIOCHEMISTRY, RESPONSE ASSESSMENT - QUESTION 2, TARGET LESIONS, NON-TARGET LESIONS DURING TREATMENT, NEW LESIONS, OTHER RADIOLOGY, ADVERSE EVENTS / INTERCURRENT ILLNESS, IP Administration -- questions, Day 1 IP Administration, CONCOMITANT MEASURES/MEDICATIONS, MAJOR MEDICAL PROBLEMS, QUALITY OF LIFE QUESTIONNAIRE, Comments, Contact Information
NCIC OV 21 Treatment Report Form Comparing Three Combination Chemotherapy Regimens in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=69B8C40D-B835-E610-E040-BB89AD43211A

Cycle Dose Drug Form (D2R) GOG-0262

- 22.08.15 - 1 form, 4 itemgroups, 38 items, 1 language
Itemgroups: HEADER MODULE, TREATMENT CYCLE AND MODIFICATION, Pretreatment hematology and chemistry values, COMMENTS
Cycle Dose Drug Form (D2R) GOG-0262 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=

Cycle Dose Drug Form (D2R) GOG-0241

- 22.08.15 - 1 form, 3 itemgroups, 42 items, 1 language
Itemgroups: HEADER MODULE, TREATMENT CYCLE AND MODIFICATION, Pretreatment hematology and chemistry values
GOG-0241 Cycle Dose Drug Form (D2R) Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=

Gynecologic Oncology Group Surgical Reporting Form (Form C) NCT00951496

- 03.07.15 - 1 form, 3 itemgroups, 21 items, 1 language
Itemgroups: HEADER MODULE, Header, Comments
Gynecologic Oncology Group Surgical Reporting Form (Form C) NCT00951496 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=4F53ABD3-7FB6-64F0-E044-0003BA3F9857

GOG-0241 Surgical Reporting Form (C) NCT01081262

- 03.07.15 - 1 form, 3 itemgroups, 21 items, 1 language
Itemgroups: HEADER MODULE, Surgery assessment, Comments
GOG-0241 Surgical Reporting Form (C) NCT01081262 Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine, With or Without Bevacizumab, as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II, Stage III, Stage IV, or Recurrent Stage I Epithelial Ovarian Cancer or Fallopian Tube Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=8D1826DA-E8EB-F792-E040-BB89AD433BF7

NCT00565851 GYNECOLOGIC ONCOLOGY GROUP Pre-Treatment Summary Form - FORM DR

- 26.06.15 - 1 form, 4 itemgroups, 21 items, 1 language
Itemgroups: Patient demographics, NON-INVASIVE DIAGNOSTIC PROCEDURES, TUMOR EVALUATION, COMMENTS
NCT00565851 GYNECOLOGIC ONCOLOGY GROUP Pre-Treatment Summary Form - FORM DR Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=DA3F819F-A88A-3FEB-E034-0003BA12F5E7

NCT00565851 GYNECOLOGIC ONCOLOGY GROUP Recurrent Gynecologic Cancer - On Study Form - FORM OSR

- 26.06.15 - 1 form, 5 itemgroups, 36 items, 1 language
Itemgroups: Patient demographics, DISEASE DESCRIPTION - PRIOR HISTORY, DISEASE DESCRIPTION - CURRENT HISTORY, PRIOR TREATMENT FOR GYNECOLOGIC CANCER, COMMENTS
NCT00565851 GYNECOLOGIC ONCOLOGY GROUP Recurrent Gynecologic Cancer - On Study Form - FORM OSR Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=DA533423-E4AA-53B9-E034-0003BA12F5E7

NCT00565851 GYNECOLOGIC ONCOLOGY GROUP Solid Tumor Evaluation Form - FORM D2M

- 26.06.15 - 1 form, 6 itemgroups, 29 items, 1 language
Itemgroups: Patient demographics, TARGET LESION(S) EVALUATION, NON-TARGET LESION(S) EVALUATION, NEW TARGET LESION(S) AT FOLLOW-UP EVALUATION, OVERALL RESPONSE, Comments
NCT00565851 GYNECOLOGIC ONCOLOGY GROUP Solid Tumor Evaluation Form - FORM D2M Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=DA2BF104-B72B-1DC3-E034-0003BA12F5E7

Concomitant Medication Form, GOG-0212, Form CMED NCT00108745

- 16.06.15 - 1 form, 3 itemgroups, 20 items, 1 language
Itemgroups: HEADER MODULE, MEDICATION INFORMATION, COMMENT
Concomitant Medication Form, GOG-0212, Form CMED NCT00108745 Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallopian Tube Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=FD45FED6-D996-72B6-E034-0003BA3F9857

GYNECOLOGIC ONCOLOGY GROUP Treatment Completion Form - FORM Q0 NCT00565851

- 03.06.15 - 1 form, 4 itemgroups, 19 items, 1 language
Itemgroups: Header module, TREATMENT SCHEDULE, OFF-TREATMENT REASON, Comments
GYNECOLOGIC ONCOLOGY GROUP Treatment Completion Form - FORM Q0 NCT00565851 Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=DA632D3C-41EC-2430-E034-0003BA12F5E7

Ovarian Cancer NCT00993655 Off Treatment - NCIC OV 21 End of Treatment Form - 2874223v1.0 - NCIC OV 21 End of Treatment Form

- 09.01.15 - 1 form, 5 itemgroups, 22 items, 1 language
Itemgroups: Patient Information, OFF PROTOCOL THERAPY , CA 125 At the End of Protocol Treatment, Comments, Contact Information
NCIC OV 21 End of Treatment Form Comparing Three Combination Chemotherapy Regimens in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=69B8C40D-B831-E610-E040-BB89AD43211A

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial